17. Ben Zirar S., Astier A., Muchow M., Gibaud S. Comparison of nanosuspensions and hydroxypropyl-ß-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur.J. Pharm. Biopharm. (sous presse)

16. Gibaud S, Astier A. Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs. Ann Pharm. Fr., 65(3), 162-168, 2007

15. Ben Zirar S, Gibaud S, Camut A, Astier A. Pharmacokinetics and tissue distribution of the antileukemic organoarsenicals arsthinol and melarsoprol in mice. J. Organometallic Chem., 692 (6 Spec Issue), 1348-1352, 2007

14. Brun H, Paul M., Gibaud S, Binhas M., Astier A. Formation and characterization of cyclodextrin inclusion complexes with Nefopam, Drug Dev. Ind. Pharm., Drug Dev. Ind. Pharm. 32, 1-12, 2006

13. S. Gibaud, A. Alfonsi, P. Muntzenhardt, I Fries, A. Astier. (2-Phenyl-[1,2,3]dithiarsolan-4-yl)methanol derivatives show in vitro antileukemic activity. J. Organometallic Chem., 2006;691(5): 1081-1084

12. S. Gibaud, S. Ben Zirar, P. Muntzenhardt, I. Fries, A. Astier. Melarsoprol-cyclodextrins inclusion complexes, Int. J. Pharm. 2005; 306: 107-121.

11. A. Astier, MJ Ferrer, S. Gibaud. Enhancement by 1-(2-chloroethyl)- 3-cyclohexyl- 1-nitrosourea (CCNU) of the cytotoxic properties of 1-ß-d-arabinofuranosylcytosine (Ara-C) on human promyelocytic leukemia cell line HL-60. Eur J Hosp Pharm Sci, 2005 ; 3 :31-36.

10. Gibaud S, Jabir Al Awwadi N, Ducki C, Astier A. Poly([epsilon]-caprolactone) and Eudragit(R) microparticles containing fludrocortisone acetate. International Journal of Pharmaceutics. 2004;269:491-508

9. Gibaud S, Bonneville A, Astier A. Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods. Int J Pharm. 2002;242:197-201

8. Gibaud S, Gaia A, Astier A. Slow-release melarsoprol microparticles. Int J Pharm. 2002;243:161-166

7 . Gibaud S, Weingarten C, Andreux JP, Couvreur P. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles]. Ann Pharm Fr. 1999;57:324-331

6. Gibaud S, Rousseau C, Weingarten C, Favier R, Douay L, Andreux JP, Couvreur P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J Control Release. 1998;52:131-139

5. Page-Clisson M-E, Gibaud S, Pinto-Alphandary H, Weingarten C, Couvreur P. Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. International Journal of Pharmaceutics. 1998;166:117-120.

4. Demoy M, Gibaud S, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharm Res. 1997;14:463-468

3 . Gibaud S, Demoy M, Andreux JP, Weingarten C, Gouritin B, Couvreur P. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci. 1996;85:944-950

2. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer. 1994;30A:820-826

1. Decool A, Goury V, Tibi A, Gibaud S, Vincent F, Darbord JC. Detection of bacterial adenosine triphosphate through bioluminescence, applied to a rapid sterility test of injectable preparations. Analytica Chimica Acta. 1991;255:423-425

 

> haut

 

[ Site internet : Christophe.Mott@univ-lorraine.fr ]